Video

Ruth Rechis on the Needs of Cancer Survivors

Author(s):

Onclive Team

Ruth Rechis from LIVESTRONG on the Key Points of Her Presentation

Ruth Rechis, PhD, a cancer survivor who is the Director of Evaluation and Research at the LIVESTRONG Lance Armstrong Foundation, talks about cancer survivors’ needs.

Related Videos
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Related Content
Updates and Advances in Early Stage Breast Cancer
April 5th 2023

Updates and Advances in Early Stage Breast Cancer

Manali Kamdar, MD
December 11th 2021

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL

Brandon Blue, MD
October 1st 2021

Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma
July 29th 2020

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma
June 11th 2020

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer
June 2nd 2020

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer